Prime Medicine (PRME) Competitors

$3.32 +0.08 (+2.31%)

As of 02:58 PM Eastern

PRME vs. BEAM, RLAY, ADMA, MLYS, and RARE

Should you buy Prime Medicine stock or one of its competitors? MarketBeat compares Prime Medicine with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Prime Medicine include Beam Therapeutics (BEAM), Relay Therapeutics (RLAY), ADMA Biologics (ADMA), Mineralys Therapeutics (MLYS), and Ultragenyx Pharmaceutical (RARE). These companies are all part of the "pharmaceutical products" industry.

How does Prime Medicine compare to Beam Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and Prime Medicine (NASDAQ:PRME) are both pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends, media sentiment and earnings.

In the previous week, Beam Therapeutics and Beam Therapeutics both had 10 articles in the media. Beam Therapeutics' average media sentiment score of 0.82 beat Prime Medicine's score of -0.13 indicating that Beam Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beam Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Prime Medicine	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Beam Therapeutics has higher revenue and earnings than Prime Medicine. Beam Therapeutics is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$139.74M	22.94	-$79.99M	-$0.68	N/A
Prime Medicine	$4.63M	129.32	-$201.14M	-$1.23	N/A

Beam Therapeutics has a net margin of -39.66% compared to Prime Medicine's net margin of -4,917.55%. Beam Therapeutics' return on equity of -29.00% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-39.66%	-29.00%	-22.61%
Prime Medicine	-4,917.55%	-188.82%	-60.97%

Beam Therapeutics has a beta of 2.26, indicating that its stock price is 126% more volatile than the broader market. Comparatively, Prime Medicine has a beta of 2.35, indicating that its stock price is 135% more volatile than the broader market.

99.7% of Beam Therapeutics shares are owned by institutional investors. Comparatively, 70.4% of Prime Medicine shares are owned by institutional investors. 3.8% of Beam Therapeutics shares are owned by insiders. Comparatively, 22.7% of Prime Medicine shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Beam Therapeutics presently has a consensus price target of $47.17, suggesting a potential upside of 51.36%. Prime Medicine has a consensus price target of $7.38, suggesting a potential upside of 122.47%. Given Prime Medicine's higher probable upside, analysts plainly believe Prime Medicine is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71
Prime Medicine	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56

Summary

Beam Therapeutics beats Prime Medicine on 10 of the 15 factors compared between the two stocks.

How does Prime Medicine compare to Relay Therapeutics?

Prime Medicine (NASDAQ:PRME) and Relay Therapeutics (NASDAQ:RLAY) are both pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends.

Prime Medicine presently has a consensus price target of $7.38, suggesting a potential upside of 122.47%. Relay Therapeutics has a consensus price target of $20.56, suggesting a potential upside of 61.08%. Given Prime Medicine's higher probable upside, equities analysts plainly believe Prime Medicine is more favorable than Relay Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prime Medicine	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56
Relay Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

Relay Therapeutics has a net margin of 0.00% compared to Prime Medicine's net margin of -4,917.55%. Relay Therapeutics' return on equity of -43.94% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prime Medicine	-4,917.55%	-188.82%	-60.97%
Relay Therapeutics	N/A	-43.94%	-40.11%

Prime Medicine has higher earnings, but lower revenue than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prime Medicine	$4.63M	129.32	-$201.14M	-$1.23	N/A
Relay Therapeutics	$15.35M	159.28	-$276.48M	-$1.57	N/A

In the previous week, Prime Medicine had 2 more articles in the media than Relay Therapeutics. MarketBeat recorded 10 mentions for Prime Medicine and 8 mentions for Relay Therapeutics. Relay Therapeutics' average media sentiment score of 0.20 beat Prime Medicine's score of -0.13 indicating that Relay Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prime Medicine	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Relay Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Prime Medicine has a beta of 2.35, suggesting that its share price is 135% more volatile than the broader market. Comparatively, Relay Therapeutics has a beta of 1.74, suggesting that its share price is 74% more volatile than the broader market.

70.4% of Prime Medicine shares are owned by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are owned by institutional investors. 22.7% of Prime Medicine shares are owned by company insiders. Comparatively, 5.0% of Relay Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Relay Therapeutics beats Prime Medicine on 9 of the 16 factors compared between the two stocks.

How does Prime Medicine compare to ADMA Biologics?

ADMA Biologics (NASDAQ:ADMA) and Prime Medicine (NASDAQ:PRME) are both pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, media sentiment, institutional ownership, earnings, profitability and analyst recommendations.

ADMA Biologics currently has a consensus target price of $19.00, suggesting a potential upside of 125.20%. Prime Medicine has a consensus target price of $7.38, suggesting a potential upside of 122.47%. Given ADMA Biologics' higher probable upside, analysts plainly believe ADMA Biologics is more favorable than Prime Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.40
Prime Medicine	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56

In the previous week, ADMA Biologics had 23 more articles in the media than Prime Medicine. MarketBeat recorded 33 mentions for ADMA Biologics and 10 mentions for Prime Medicine. ADMA Biologics' average media sentiment score of 0.22 beat Prime Medicine's score of -0.13 indicating that ADMA Biologics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADMA Biologics	7 Very Positive mention(s)	1 Positive mention(s)	17 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral
Prime Medicine	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ADMA Biologics has a net margin of 32.43% compared to Prime Medicine's net margin of -4,917.55%. ADMA Biologics' return on equity of 39.98% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	32.43%	39.98%	28.08%
Prime Medicine	-4,917.55%	-188.82%	-60.97%

ADMA Biologics has higher revenue and earnings than Prime Medicine. Prime Medicine is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$510.17M	3.94	$146.93M	$0.68	12.41
Prime Medicine	$4.63M	129.32	-$201.14M	-$1.23	N/A

75.7% of ADMA Biologics shares are held by institutional investors. Comparatively, 70.4% of Prime Medicine shares are held by institutional investors. 3.9% of ADMA Biologics shares are held by insiders. Comparatively, 22.7% of Prime Medicine shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

ADMA Biologics has a beta of 0.83, suggesting that its stock price is 17% less volatile than the broader market. Comparatively, Prime Medicine has a beta of 2.35, suggesting that its stock price is 135% more volatile than the broader market.

Summary

ADMA Biologics beats Prime Medicine on 11 of the 17 factors compared between the two stocks.

How does Prime Medicine compare to Mineralys Therapeutics?

Mineralys Therapeutics (NASDAQ:MLYS) and Prime Medicine (NASDAQ:PRME) are both pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, media sentiment, earnings, risk and dividends.

84.5% of Mineralys Therapeutics shares are held by institutional investors. Comparatively, 70.4% of Prime Medicine shares are held by institutional investors. 18.9% of Mineralys Therapeutics shares are held by insiders. Comparatively, 22.7% of Prime Medicine shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Mineralys Therapeutics had 9 more articles in the media than Prime Medicine. MarketBeat recorded 19 mentions for Mineralys Therapeutics and 10 mentions for Prime Medicine. Mineralys Therapeutics' average media sentiment score of 0.10 beat Prime Medicine's score of -0.13 indicating that Mineralys Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mineralys Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Prime Medicine	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Mineralys Therapeutics presently has a consensus target price of $49.14, suggesting a potential upside of 68.46%. Prime Medicine has a consensus target price of $7.38, suggesting a potential upside of 122.47%. Given Prime Medicine's higher possible upside, analysts clearly believe Prime Medicine is more favorable than Mineralys Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mineralys Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Prime Medicine	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56

Mineralys Therapeutics has a beta of 0.49, indicating that its stock price is 51% less volatile than the broader market. Comparatively, Prime Medicine has a beta of 2.35, indicating that its stock price is 135% more volatile than the broader market.

Mineralys Therapeutics has a net margin of 0.00% compared to Prime Medicine's net margin of -4,917.55%. Mineralys Therapeutics' return on equity of -27.92% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mineralys Therapeutics	N/A	-27.92%	-26.98%
Prime Medicine	-4,917.55%	-188.82%	-60.97%

Mineralys Therapeutics has higher earnings, but lower revenue than Prime Medicine. Mineralys Therapeutics is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$2.05	N/A
Prime Medicine	$4.63M	129.32	-$201.14M	-$1.23	N/A

Summary

Mineralys Therapeutics beats Prime Medicine on 9 of the 16 factors compared between the two stocks.

How does Prime Medicine compare to Ultragenyx Pharmaceutical?

Prime Medicine (NASDAQ:PRME) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership, profitability and media sentiment.

Prime Medicine has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prime Medicine	$4.63M	129.32	-$201.14M	-$1.23	N/A
Ultragenyx Pharmaceutical	$673M	3.88	-$575M	-$6.11	N/A

70.4% of Prime Medicine shares are owned by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. 22.7% of Prime Medicine shares are owned by company insiders. Comparatively, 5.2% of Ultragenyx Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Prime Medicine has a beta of 2.35, suggesting that its stock price is 135% more volatile than the broader market. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.39, suggesting that its stock price is 61% less volatile than the broader market.

Prime Medicine presently has a consensus price target of $7.38, indicating a potential upside of 122.47%. Ultragenyx Pharmaceutical has a consensus price target of $60.41, indicating a potential upside of 127.77%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher possible upside, analysts plainly believe Ultragenyx Pharmaceutical is more favorable than Prime Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prime Medicine	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83

Ultragenyx Pharmaceutical has a net margin of -91.03% compared to Prime Medicine's net margin of -4,917.55%. Prime Medicine's return on equity of -188.82% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prime Medicine	-4,917.55%	-188.82%	-60.97%
Ultragenyx Pharmaceutical	-91.03%	-1,024.42%	-45.78%

In the previous week, Ultragenyx Pharmaceutical had 23 more articles in the media than Prime Medicine. MarketBeat recorded 33 mentions for Ultragenyx Pharmaceutical and 10 mentions for Prime Medicine. Ultragenyx Pharmaceutical's average media sentiment score of 0.07 beat Prime Medicine's score of -0.13 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prime Medicine	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ultragenyx Pharmaceutical	8 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Ultragenyx Pharmaceutical beats Prime Medicine on 9 of the 16 factors compared between the two stocks.

Get Prime Medicine News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRME and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRME vs. The Competition

Export

Metric	Prime Medicine	Biological Products, Except Diagnostic Substances Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$598.76M	$372.81M	$4.25B	$12.10B
Dividend Yield	N/A	N/A	5.78%	5.23%
P/E Ratio	-2.70	N/A	23.50	25.41
Price / Sales	129.32	67.56	150.04	75.53
Price / Cash	N/A	N/A	49.53	36.29
Price / Book	4.95	2.87	36.72	6.65
Net Income	-$201.14M	-$81.71M	$114.78M	$333.40M
7 Day Performance	-2.21%	2.67%	0.41%	-0.58%
1 Month Performance	-3.35%	9.39%	4.46%	7.66%
1 Year Performance	N/A	N/A	20.05%	35.36%

Prime Medicine Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRME Prime Medicine	2.0575 of 5 stars	$3.32 +2.3%	$7.38 +122.5%	N/A	$598.76M	$4.63M	N/A	N/A	Earnings Report Analyst Revision
BEAM Beam Therapeutics	3.9949 of 5 stars	$28.90 -3.9%	$49.36 +70.8%	+82.3%	$3.09B	$139.74M	N/A	510	Earnings Report
RLAY Relay Therapeutics	2.7036 of 5 stars	$13.00 -0.7%	$20.56 +58.1%	+326.9%	$2.50B	$15.35M	N/A	330	Earnings Report Analyst Downgrade
ADMA ADMA Biologics	4.4404 of 5 stars	$10.25 -0.6%	$25.67 +150.4%	-60.6%	$2.46B	$510.17M	17.08	530	Earnings Report
MLYS Mineralys Therapeutics	3.8189 of 5 stars	$29.28 -1.2%	$49.14 +67.8%	+102.9%	$2.44B	N/A	N/A	28	Earnings Report Analyst Downgrade Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PRME) was last updated on 5/12/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Prime Medicine (PRME) Competitors

PRME vs. BEAM, RLAY, ADMA, MLYS, and RARE

How does Prime Medicine compare to Beam Therapeutics?

Summary

How does Prime Medicine compare to Relay Therapeutics?

Summary

How does Prime Medicine compare to ADMA Biologics?

Summary

How does Prime Medicine compare to Mineralys Therapeutics?

Summary

How does Prime Medicine compare to Ultragenyx Pharmaceutical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRME vs. The Competition

Prime Medicine Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Prime Medicine (PRME) Competitors

PRME vs. BEAM, RLAY, ADMA, MLYS, and RARE

How does Prime Medicine compare to Beam Therapeutics?

Does the media prefer BEAM or PRME?

Which has preferable valuation & earnings, BEAM or PRME?

Is BEAM or PRME more profitable?

Which has more risk & volatility, BEAM or PRME?

Do insiders and institutionals hold more shares of BEAM or PRME?

Do analysts recommend BEAM or PRME?

Summary

How does Prime Medicine compare to Relay Therapeutics?

Do analysts rate PRME or RLAY?

Is PRME or RLAY more profitable?

Which has stronger valuation and earnings, PRME or RLAY?

Does the media favor PRME or RLAY?

Which has more volatility & risk, PRME or RLAY?

Do institutionals and insiders have more ownership in PRME or RLAY?

Summary

How does Prime Medicine compare to ADMA Biologics?

Do analysts prefer ADMA or PRME?

Does the media refer more to ADMA or PRME?

Is ADMA or PRME more profitable?

Which has stronger earnings and valuation, ADMA or PRME?

Do institutionals & insiders believe in ADMA or PRME?

Which has more volatility & risk, ADMA or PRME?

Summary

How does Prime Medicine compare to Mineralys Therapeutics?

Do insiders & institutionals have more ownership in MLYS or PRME?

Does the media favor MLYS or PRME?

Do analysts prefer MLYS or PRME?

Which has more volatility & risk, MLYS or PRME?

Is MLYS or PRME more profitable?

Which has higher valuation & earnings, MLYS or PRME?

Summary

How does Prime Medicine compare to Ultragenyx Pharmaceutical?

Which has better valuation and earnings, PRME or RARE?

Do insiders and institutionals believe in PRME or RARE?

Which has more volatility & risk, PRME or RARE?

Do analysts recommend PRME or RARE?

Is PRME or RARE more profitable?

Does the media refer more to PRME or RARE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRME vs. The Competition

Prime Medicine Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools